IGI Logo

Marksans Pharma is currently trading at Rs. 313.90, up by 5.35 points or 1.73% from its previous closing of Rs. 308.55 on the BSE.

The scrip opened at Rs. 318.00 and has touched a high and low of Rs. 318.70 and Rs. 310.00 respectively. So far 51508 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 328.35 on 20-Sep-2024 and a 52 week low of Rs. 126.05 on 14-Mar-2024.

Last one week high and low of the scrip stood at Rs. 319.00 and Rs. 297.25 respectively. The current market cap of the company is Rs. 14190.82 crore.

The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 25.41% and 30.71% respectively.

Marksans Pharma has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.

They are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from ‘hay fever’ and other allergies.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.